$EXEL News

Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to $53

Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Barclays Maintains Equal-Weight on Exelixis, Raises Price Target to $49

Wells Fargo Maintains Equal-Weight on Exelixis, Raises Price Target to $49

Is Exelixis (EXEL) Expensive After Its Recent Rally Or Still Undervalued?

Exelixis (EXEL) Stock Trades At A Discount After Its 236% Run

Exelixis: STELLAR-303 Results Mixed, STELLAR-304 Success Likely

Is Exelixis, Inc. (EXEL) Among the Best Under-the-Radar Stocks to Invest In?

Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue?

RBC Capital Maintains Sector Perform on Exelixis, Raises Price Target to $46

Truist Securities Maintains Hold on Exelixis, Raises Price Target to $56

Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says

UBS Maintains Neutral on Exelixis, Raises Price Target to $52

HC Wainwright & Co. Reiterates Buy on Exelixis, Maintains $56 Price Target

Exelixis Inc. (NASDAQ:EXEL): A Decent Value Play in the Biotechnology Sector

Truist Securities Downgrades Exelixis to Hold, Raises Price Target to $54

Citizens Maintains Market Outperform on Exelixis, Raises Price Target to $55

Exelixis Provides 'A Highly Defensive Investment Profile:' Analyst